Resources
News
RebrAIn Achieves MDR Certification for OptimMRI, Expanding Access to Precision Neurosurgery Across Europe
Already FDA 510(k) cleared in 2024, OptimMRI is an AI-powered surgical planning platform that supports Deep Brain Stimulation (DBS) and lesioning procedures (HIFU & Radiosurgery) targeting the STN and VIM regions. With MDR certification now secured, RebrAIn is...
RebrAIn joins the Charter for the Responsible Development of Neurotechnologies
RebrAIn is proud to announce its commitment to the Charter for the Responsible Development of Neurotechnologies, a collective initiative led by public and private stakeholders and supported by the French National Consultative Ethics (CCNE). This initiative is part of...
Challenges showcases RebrAIn’s AI-powered innovation in Parkinson’s surgery
Challenges underscores the significance of RebrAIn's technology in enhancing the precision and efficiency of deep brain stimulation (DBS) surgeries. By leveraging machine learning algorithms trained on extensive clinical data, RebrAIn's software assists neurosurgeons...
From Patient to Practice: RebrAIn Wins the Resah Tender
The Strategic Importance of This Tender This success marks a major strategic turning point for RebrAIn, as the Resah procurement center plays a key role in the public healthcare sector in France. By enabling the member hospitals to choose the most effective...
The FUS Foundation highlights RebrAIn’s advances and validates its Board
Recently, the Focused Ultrasound Foundation highlighted RebrAIn's success in obtaining its second FDA 510(k) approval - which extends the capabilities of its OptimMRI software to include new machine learning models for lesioning treatment of Essential Tremor, thereby...
RebrAIn Hosts Inaugural Medical Advisory Board Meeting (MAB)
RebrAIn recently held the inaugural meeting of its Medical Advisory Board (MAB), marking a significant milestone in the company’s ongoing mission to deliver transformative AI-powered tools to neurosurgeons. The meeting also underscored RebrAIn's pivotal role in...
User’s manual
Last release
OptimMRI US
OptimDBS EU
- CUG_OptimDBS-IT-Rev_4.pdf (Revision #4 | Revision date: 2024-06 | Lang.: IT)
- CUG_OptimDBS-EN-Rev_4.pdf (Revision #4 | Revision date: 2024-06 | Lang.: EN)
- CUG_OptimDBS-ES-Rev_4.pdf (Revision #4| Revision date: 2024-06 | Lang.: ES)
- CUG_OptimDBS-FR-Rev_4.pdf (Revision #4 | Revision date: 2024-06 | Lang.: FR)
Information notice
All revisions of the instructions manual are available for download below, in English and other languages. This manual details how to retreive and use the marked MRIs for surgery planning. Marked MRIs (3D DICOM) contain the targets as predicted by OptimDBS, a standalone tool developed by RebrAIn.
The use of those marked MRIs processed by OptimDBS is restricted to clinicians planning neurosurgery for patients with either Parkinson’s disease or essential tremor, by targeting the subthalamic nucleus (STN) or the ventral intermediate nucleus of the thalamus (VIM).
Carefully reading this instructions manual before use is strongly advised.
Any type of inappropriate use is prohibited.
A hard copy of this instructions manual can be obtained within 5 working days with no extra charge by contacting Rebrain at the following email address: support@rebrain.eu.
RebrAIn provides its partners with an access to its secure medical data exchange platform at transfer.rebrain.eu. Please contact our team with the above email address or via this website’s contact form to request an account. The current version of the instructions manual is also available for download on the data exchange platform, through the help menu of a connected account.
The instructions manuals below are available in PDF format. Any standard PDF reader, such as Acrobat Reader or Okular, is necessary
Sont disponibles dans la liste ci-dessous toutes les versions du manuel d’utilisation électronique en Français et dans d’autres langues. Ce manuel d’utilisation explique comment récupérer et utiliser lors la planification de la chirurgie les IRM marquées avec des cibles cérébrales prédites par OptimDBS, un logiciel autonome conçu par RebrAIn.
L’utilisation de ces images IRM (3D DICOM) marquées traitées avec OptimDBS est réservée au clinicien prévoyant d’effectuer une intervention neurochirurgicale pour le traitement de patient atteints de la maladie de Parkinson ou de Tremblements Essentiels en ciblant le noyau sous-thalamique, STN, ou le noyau ventral intermédiaire, VIM.
Il est recommandé de lire attentivement ce manuel d’instructions avant utilisation.
Toute utilisation inappropriée est interdite.
Une copie imprimée des instructions d’utilisation peut être obtenue dans les 5 jours ouvrés sans frais supplémentaires en contactant RebrAIn à l’adresse email suivante : support@rebrain.eu.
RebrAIn offre à ses collaborateur un accès à son service sécurisé d’échange de données médicales à transfer.rebrain.eu. Vous pouvez contacter l’équipe via le formulaire de contact pour faire la demande d’un compte. La version courante du manuel d’utilisation électronique est également accessible depuis le menu « Aide » sur la plateforme transfer.rebrain.eu une fois connecté à celle-ci.
Ces instructions d’utilisation sont fournies en format « PDF ». Un logiciel approprié, tel que Adobe Acrobat Reader, est requis pour les lire.
Archives
- CUG_OptimDBS-IT-Rev_3.pdf (Revision #3 | Revision date: 2022-06 | Lang.: IT)
- CUG_OptimDBS-EN-Rev_3.pdf (Revision #3 | Revision date: 2022-06 | Lang.: EN)
- CUG_OptimDBS-ES-Rev_3.pdf (Revision #3 | Revision date: 2022-06 | Lang.: ES)
- CUG_OptimDBS-FR-Rev_3.pdf (Revision #3 | Revision date: 2022-06 | Lang.: FR)
- CUG_OptimDBS EN Rev.2.pdf (Revision #2 | Revision date: 2021-10 | Lang.: EN)
- CUG_OptimDBS FR Rev.2.pdf (Revision #2 | Revision date: 2021-10 | Lang.: FR)
Publications
White Paper
OptimMRI from RebrAIn
A personalized, participative, preventive, predictive and evidence-based neurosurgical targeting service for patients with movement disorders caused by Parkinson’s Disease or Essential Tremor.
To receive our complete white paper on OptimMRI, please submit your request via the form below. Your details will help us verify eligibility and ensure the information is sent to the right audience.
